UDK: 616.12-005.4-037 + 616.72-002.77(470.45)
A. R. Babaeva, E. V. Kalinina, K. S. Solodenkova1, M. A. Osadchuk1
Волгоградский государственный медицинский университет, 1Первый Московский государственный университет им. И. М. Сеченова
In this publication the problem of cardiovascular comorbidity in the most common rheumatic disorders was discussed. The pathogenesis and clinical features of cardiovascular diseases (CVD) in rheumatoid arthritis and other inflammatory lesions of joints were analyzed. Practical issues of cardiovascular risk evaluation and CVD prevention in rheumatoid arthritis patients were addressed according to the current national and EULAR guidelines. The cardiovascular safety of diseasemodifying drugs, including biologics, was highlighted. Evidence-based recommendations for cardiovascular risk management in patients with inflammatory arthritis were summarized.
cardiovascular risk, rheumatoid arthritis, drug treatment, biologics.
Бабаева Аида Руфатовна — д. м. н., профессор, зав. кафедрой факультетской терапии, Волгоградский государственный медицинский университет, e-mail: arbabaeva@list.ru